CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

January 3, 2019 admin CEO Interview, Healthcare, Spotlight Stocks Comments Off on CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019
Nader Pourhassan, Ph.D

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Nader Pourhassan, Ph.D

 

 

 

 

 

 

 

 

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.

The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019. 

Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer. 

Investor Presentation

CytoDyn_Investor_Presentation




Related Articles